The expression vector encodes aa residues 10 of human ngr1 with the cys266ala and cys309ala substitutions fused to the fc domain of human igg1, as described for rat protein previously. Ct invests in yale alzheimers therapy hartford business. New havenbased biotech company advances innovative treatments for neurological injuries and diseases. Guidelines for the management of degenerative cervical myelopathy and acute spinal cord injury. Cara tannenbaum, who was appointed by nemer to help lead the cancovid. Facebook view on facebook linkedin view on linkedin contact email kim. Intarcia therapeutics is dedicated to redesigning the treatment of chronic disease. Axerion therapeutics is a biotech company focused on developing innovative. A branford diagnostics biotech that developed a handheld device to detect organisms that cause infectious diseases is expanding its footprint in the shoreline town with a planned move to a new 16,200squarefoot facility. The awards were made pursuant to the nasdaq inducement grant exception as a component of the new hires employment.
It forms a new principle to treat chronic or postoperative pain by a peripheral acting. George maynard president and chief scientific officer. Traumatic spinal cord injurys secondary injury cascade the secondary injury cascade is a series of changes that begin within just a few hours after the sci and may continue months past the initial injury. Human ngrfc decoy protein via lumbar intrathecal bolus. Using proprietary assays, cognition therapeutics inc. Based at yale university in new haven, the team found that mice with ab plaques but no prpc showed no cognitive impairment. Degenerative cervical myelopathy, spinal cord injury. The production of human ngr10fc by expression in a stable chos cell line at axerion therapeutics has been described. Jane pritchett henderson has been appointed vp of business development for ista. Ptct today announced that on october 25, 2019 it approved nonstatutory stock options to purchase an aggregate of 339,875 shares of its common stock to 27 new employees. The company is also using chitin as the basis for programs in novel allergy and asthma therapies, vaccine adjuvants, and nutritional products. We are driven to continuously innovate and create meaningful value in all we do to help patients and families fully live their best lives. Axerion therapeutics october 2010 january 2014 3 years 4.
Therapeutics definition of therapeutics by the free. With technology licensed from the university of tuebingen, ovesco endoscopy has set out to address one of the biggest challenges of notes procedures. Alrn, the clinicalstage leader in the field of stabilized, cellpermeating peptides, announced today the promotion of richard j. The current knowledge of the role of ldha in the brain and its potential as a therapeutic target for brain tumors will also be highlighted. Wanstall to chief financial officer and treasurer, effective immediately. We are rethinking the future of medicine with people at the center of the experience. Gaba and schizophrenia targets and emerging therapies. Axerion of new haven, connecticut, through its eli. Axerion therapeutics is focused on the research and development of therapeutics for neurological diseases and injuries. The regulation and function of lactate dehydrogenase a. A read is counted each time someone views a publication summary such as the title, abstract, and list of authors, clicks on a figure, or views or downloads the fulltext. The work we do is guided by people living with rare and devastating diseases. Aspyrian therapeutics is a clinical stage oncology company developing novel precisiontargeted therapies based on the photoimmunotherapy technology pit platform.
On the day the auction is set to close, each lot will clearly countdown the time left until closing. Axerion was established in new haven to develop and commercialize intellectual property licensed from dr. Fimbrion therapeautics pioneers antivirulence solutions to treat utis. Contact siteone therapeutics, headquartered in bozeman, montana with a research team in south san francisco, california, is dedicated to developing novel pain therapeutics to safely, effectively and efficiently treat acute and chronic pain without the limitations of existing drugs, such as opioids. New haven, ct, usa i may 1, 2012 i axerion therapeutics, inc. Axerion of new haven, connecticut, through its eli whitney fund. Branford biotech expanding to bigger space after raising. About us celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. The lots will have a staggered closing time with 2 closing every minute in numerical order. Antivirulence cmannosides as antibioticsparing, oral therapeutics for urinary tract infections. The project involves developing a compound nogo receptor decoy to rewire nerve cells that promote the recovery of neurological function. This drug is currently developed by cara therapeutics. A corporate filing is called a foreign filing when an existing corporate entity files in a state other than the.
He and his team spent a halfdozen years investigating the bodys inability to repair itself following injury to the central nervous system, and developing a drug to block growth inhibitors. Hyperion therapeutics is a biopharmaceutical company focused on creating treatments for urea cycle disorders and other rare diseases. If you do not receive an email within 10 minutes, your email address may not be registered, and you may need to create a new wiley online library. Regulation of axonal regeneration by the level of function. After more than doubling, esperion therapeutics, inc. He has focused his academic and business career on the application of developmental biology to. It could be the source of a treatment for the common cold, too. See who you know at axerion therapeutics, leverage your professional network, and get hired. Intravitreal delivery of human ngrfc decoy protein. Fimbrion and gsk to develop novel antibacterial therapy for urinary tract infections. Stock protein solutions at 10 mgml were stable for greater than 1 year at.
Our pipeline includes immunotherapies and other targeted biologics derived from a broad set of complementary technologies which have the ability to engage the human immune system andor directly inhibit tumors to treat specific types of cancer or other diseases. You are cordially invited to attend the 2018 annual meeting of stockholders of axsome therapeutics, inc. Cara, a biopharmaceutical company focused on developing. Renetxs erika smith fights the good fight against spinal. Branford is cts quiet bioscience startup hub hartford. Biotechcareers is funded in part by the national science foundation. Ptc therapeutics reports inducement grants under nasdaq. Intarcia therapeutics rethinking the future of medicine. Learn how to convert outlook e mails to pdf with adobe acrobat in windows 1087. Aileron therapeutics announces the promotion of richard j. Pdf cr845 difelikefalin, a kappa receptors agonist in phase iii. Clinical practice guidelines for the management of degenerative cervical myelopathy and acute traumatic spinal cord injury.
Siteone therapeutics is dedicated to developing novel pain therapeutics to safely, effectively and efficiently treat acute and chronic pain without the limitations of existing drugs, such as opioids. Alzheimers disease ad is a devastating neurodegenerative disorder, afflicting more than onethird of people over the age of 85. Pit utilizes antibody conjugates that accumulate at the tumor after systemic infusion and can be activated with light to induce rapid, specific, and robust tumor destruction. Translational neuropharmacology consulting, llc, potomac, md, usa. Alexion is a global biopharmaceutical company focused on developing lifechanging therapies for people living with rare disorders. Henderson was most recently chief financial officer and executive vp. Addex therapeutics is a clinicalstage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.
While many therapies for ad are in latestage clinical testing, rational drug design based on distinct signaling pathways in this disorder is only now emerging. This months profile group, alzheimers startups face a discovery and clinical crossroads, features profiles of alzprotect, axerion therapeutics, cognition therapeutics and galantos pharma. Ovesco has developed a clipping system that imitates the mechanics the geometry and force pattern of a surgical suture, but with advantages. In 2010, strittmatter formed a company called axerion therapeutics with the yale office of cooperative research. View george maynards profile on linkedin, the worlds largest professional community. Living with a rare disease isnt just about the treatment, its also about channeling uncertainty and fear into something.
Chitin may be the second most common molecule on earth. Abstract axonal growth and neurological recovery after traumatic spinal cord injury sci is limited by the presence of inhibitory proteins in myelin, several of which act via the ngr1 protein in n. Human ngr10fc was expressed in a stable chos cell line at axerion therapeutics. Development of nogo receptor decoy for the treatment of spinal cord injury, george maynard, phd, axerion therapeutics, inc. Intravitreal delivery of human ngrfc decoy protein regenerates. Fyn kinase inhibition as a novel therapy for alzheimers.
644 1526 472 147 1007 606 823 1400 1222 735 974 584 355 1366 1265 379 1088 1550 853 1429 212 90 224 357 50 1073 801 1156 62 1170 1459 819 1218 864 379 852 1043 1455